title: Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial.
abstract: The efficacy and field safety of marbofloxacin (Zeniquin) for the treatment of superficial and deep bacterial pyoderma were evaluated. Seventy-two dogs were treated with 2.75 mg kg-1 of marbofloxacin orally once daily for 21 or 28 days. Sixty-two dogs (86%) had superficial pyoderma and 10 (14%) had deep pyoderma. A history of prior pyoderma was reported in 39/72 dogs. Pretreatment aerobic bacteriologic cultures of skin lesions were performed in 47 cases and the predominant pathogen isolated was Staphylococcus intermedius. Treatment was successful in 62/72 (86.1%) dogs, improvement was noted in 6/72 (8.3%) dogs and treatment failed in 4/72 (5.6%) dogs. Adverse effects associated with treatment included listlessness, anorexia, vomiting, soft stool, flatulence and polydipsia; these adverse effects were seen in only 6/81 dogs. Marbofloxacin was safe and effective for the treatment of superficial and deep pyoderma in dogs at the dosage used in this study.
authors: Department of Clinical Sciences, Faculté de médecine vétérinaire, Université de Montréal, CP 5000, St-Hyacinthe, Québec, Canada, J2S 7C6. paradima@medvet.umontreal.ca
authors: M
authors: M
authors: Paradis
authors: L
authors: L
authors: Abbey
authors: B
authors: B
authors: Baker
authors: M
authors: M
authors: Coyne
authors: M
authors: M
authors: Hannigan
authors: D
authors: D
authors: Joffe
authors: B
authors: B
authors: Pukay
authors: A
authors: A
authors: Trettien
authors: S
authors: S
authors: Waisglass
authors: J
authors: J
authors: Wellington
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001947:Breeding; D002170:Canada; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D024841:Fluoroquinolones; D008297:Male; D011711:Pyoderma / Q000188:drug therapy / Q000662:veterinary*; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000662:veterinary*; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C080260:marbofloxacin